JAFL
MRTX

Jay A. Fishman Ltd’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Jay A. Fishman Ltd’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,000
Closed -$218K – 97
2023
Q3 		$218K Buy
+5,000
New +$179K 0.03% 88
2023
Q1 		– Sell
-5,000
Closed -$227K – 96
2022
Q4 		$227K Buy
+5,000
New +$324K 0.03% 89

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Jay A. Fishman Ltd's MRTX Position: Q4 2023 in Review

Jay A. Fishman Ltd sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 5,000 shares — an estimated $218K sold.

Jay A. Fishman Ltd first reported a position in MRTX in Q4 2022 and held it in 2 quarters. The position peaked at $227K in Q4 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Jay A. Fishman Ltd reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Jay A. Fishman Ltd sold 5,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $218K.
  • Jay A. Fishman Ltd first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Jay A. Fishman Ltd's Mirati Therapeutics, Inc. Common Stock position peaked at $227K in Q4 2022.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Jay A. Fishman Ltd's 13F filing for Q4 2023, filed 24 Jan 2024.